Merck

MRK NYSE
Overview Stats Financials News

Yahoo Finance • a month ago

Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript

Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.07, expectations were $1.94. Merck & Co., Inc. isn’t one of the 30 most popular stocks among he... Full story

Yahoo Finance • 2 months ago

11 Hot Growth Stocks To Buy Right Now

In this article, we discuss the 11 hot growth stocks to buy now. If you want to read about some more growth stocks that are active in the market, go directly to the 5Hot Growth Stocks To Buy Right Now. As 2024 moves forward, the outlook f... Full story

Yahoo Finance • 2 months ago

13 Best Low Volatility Stocks to Buy According to Hedge Funds

In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds.... Full story

Yahoo Finance • 2 months ago

10 Best Weight Loss Drug Stocks to Buy Now

In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it's one of the biggest trends on the stock market right now, then... Full story

Yahoo Finance • 2 months ago

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults

Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results and represents the sixth approval for KEYTRUDA in lung cancer in Europe RAHWAY, N.J., March 28, 2024--(... Full story

Yahoo Finance • 2 months ago

US STOCKS-Futures tick up in thin trading week, Fed commentary in focus

(For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window.) * GameStop faces 'unsustainable' sales decline, shares slide * Merck up after FDA approves therapy for rare lung condition * Mega... Full story

Yahoo Finance • 2 months ago

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)

WINREVAIR logo (Graphic: Merck & Co., Inc.) Product image (Photo: Merck & Co., Inc.) Product image (Photo: Merck & Co., Inc.) Product image (Photo: Merck & Co., Inc.) Product image (Photo: Merck & Co., Inc.) WINREVAIR is a breakthrough bi... Full story

Yahoo Finance • 3 months ago

13 Best Pharma Dividend Stocks To Buy in 2024

In this article, we discuss 13 best pharma dividend stocks to buy in 2024. You can skip our detailed analysis of the pharma sector and its performance, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2024. Within the healt... Full story

Yahoo Finance • 3 months ago

New York attorney general urges stronger safety warning on asthma drug Singulair

By Robin Respaut and Dan Levine Feb 23 (Reuters) - The attorney general for one of the most populous U.S. states this week urged federal drug regulators to address safety risks associated with the widely used asthma and allergy medicine S... Full story

Yahoo Finance • 3 months ago

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Opinion granted based on positive overall survival and event-free survival results from the Phase 3 KEYNOTE-671 trial First opinion to be granted for an anti-PD-1/L1 therapy in resectable non-small cell lung cancer (NSCLC) based on positi... Full story

Yahoo Finance • 3 months ago

Is Merck (NYSE:MRK) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually... Full story

Yahoo Finance • 3 months ago

20 Fastest Growing Biotech Companies in the US

In this article, we will be taking a look at the 20 fastest growing biotech companies in the US. If you are not interested in learning about the landscape of biotech companies, head straight to the 5 Fastest Growing Biotech Companies In Th... Full story

Yahoo Finance • 4 months ago

FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Acceptance based on results from the pivotal Phase 3 NRG-GY018 trial Results showed KEYTRUDA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy... Full story

Yahoo Finance • 4 months ago

15 Best Stocks For Long Term Growth

In this piece, we will look at the 15 best stocks for long-term growth. If you want to skip our introduction to the current drivers of stock market performance, then check out 5 Best Stocks For Long Term Growth. The stock market in 2024 i... Full story

Yahoo Finance • 4 months ago

With 78% ownership, Merck & Co., Inc. (NYSE:MRK) boasts of strong institutional backing

Key Insights Institutions' substantial holdings in Merck implies that they have significant influence over the company's share price 44% of the business is held by the top 25 shareholders Insiders have sold recently To get a sense of who... Full story

Yahoo Finance • 4 months ago

Recession's Shadow Casts Doubt On Soft Landing: Safeguard Your Portfolio With These Stocks

The stronger-than-expected U.S. jobs data for January has caused the Federal Reserve to push back its deadline for rate cuts. While the markets anticipated the central bank to begin easing interest rates from as early as March, Federal Res... Full story

Yahoo Finance • 4 months ago

Pfizer: A Cheap Stock Lacking a Catalyst

Finding stocks that trade at low valuations is fairly easy as there are many companies with weak prospects trading at low valuations. However, many of those companies are cheap for a reason and lack a catalyst to drive a valuation re-ratin... Full story

Yahoo Finance • 4 months ago

Bayer AG Emerges as a New Key Player in Kahn Brothers' Portfolio with a 1.04% Stake

Insights from Kahn Brothers (Trades, Portfolio)' Latest 13F Filing for Q4 2023 Warning! GuruFocus has detected 9 Warning Signs with AGO. Kahn Brothers (Trades, Portfolio) Group, a stalwart in the value investing arena, has disclosed its... Full story

Yahoo Finance • 4 months ago

14 Best US Stocks For Foreign Investors

In this article, we discuss the 14 best US stocks for foreign investors. If you want to read about some more US stocks that foreigners should consider for their portfolios, go directly to the 5 Best US Stocks For Foreign Investors. Late l... Full story

Yahoo Finance • 4 months ago

Merck & Co Inc EVP, Chief Info & Digital Officer David Williams Sells 1,451 Shares

David Williams, EVP, Chief Information & Digital Officer of Merck & Co Inc (NYSE:MRK), has sold 1,451 shares of the company on February 7, 2024, according to a recent SEC Filing. The transaction was executed at an average price of $127.57... Full story